Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016, provides an overview of the Wilms' Tumor (Nephroblastoma) (Oncology) pipeline landscape. Wilms' tumor or nephroblastoma is cancer of the kidneys that typically occurs in children, rarely in adults. Its common name is an eponym.Wilms' tumor is a rare kidney cancer that primarily affects children.Wilms' tumor most often occurs in just one kidney, though it can sometimes be found in both kidneys at the same time. Typical symptoms are: an abnormally large abdomen, abdominal pain, fever, nausea and vomiting, blood in the urine (in about 20% of cases) and high blood pressure in some cases. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Wilms' Tumor (Nephroblastoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively. Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Wilms' Tumor (Nephroblastoma) (Oncology). - The pipeline guide reviews pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Wilms' Tumor (Nephroblastoma) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Wilms' Tumor (Nephroblastoma) Overview 6 Therapeutics Development 7 Pipeline Products for Wilms' Tumor (Nephroblastoma) - Overview 7 Pipeline Products for Wilms' Tumor (Nephroblastoma) - Comparative Analysis 8 Wilms' Tumor (Nephroblastoma) - Therapeutics under Development by Companies 9 Wilms' Tumor (Nephroblastoma) - Therapeutics under Investigation by Universities/Institutes 10 Wilms' Tumor (Nephroblastoma) - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Wilms' Tumor (Nephroblastoma) - Products under Development by Companies 13 Wilms' Tumor (Nephroblastoma) - Products under Investigation by Universities/Institutes 14 Wilms' Tumor (Nephroblastoma) - Companies Involved in Therapeutics Development 15 Exelixis Inc 15 NanoSmart Pharmaceuticals Inc 16 Recombio SL 17 Selvita SA 18 Wilms' Tumor (Nephroblastoma) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 cabozantinib s-malate - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Cellular Immunotherapy for Oncology - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Monoclonal Antibody Conjugate for Wilms' Tumor - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 racotumomab - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 SEL-12034 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Wilms' Tumor (Nephroblastoma) - Dormant Projects 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016 7 Number of Products under Development for Wilms' Tumor (Nephroblastoma) - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Wilms' Tumor (Nephroblastoma) - Pipeline by Exelixis Inc, H2 2016 15 Wilms' Tumor (Nephroblastoma) - Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016 16 Wilms' Tumor (Nephroblastoma) - Pipeline by Recombio SL, H2 2016 17 Wilms' Tumor (Nephroblastoma) - Pipeline by Selvita SA, H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Wilms' Tumor (Nephroblastoma) - Dormant Projects, H2 2016 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.